Breaking News: Major Health Sector Developments Unveiled

This summary covers recent significant events in the health sector, including major deals, court decisions, new drug approvals, and a tragic incident involving a UnitedHealth executive. Notable mentions include Novavax's sale to Novo Nordisk, US court ruling on Novartis, Merus's FDA approval, and a new role for AstraZeneca's executive.

This week, significant movements were noted in the health sector, starting with Novavax announcing the sale of its Czech manufacturing plant to Novo Nordisk for $200 million. The funds are intended to bolster Novavax's vaccine pipeline as the company strives to compete with industry giants Moderna and Pfizer.

In regulatory affairs, the U.S. appeals court has dismissed Novartis's bid to block a generic version of its heart drug, Entresto. This ruling allows MSN Pharmaceuticals to proceed with their generic in the U.S., marking a crucial moment for drug accessibility and patent law.

The health sector was also rocked by the tragic news of UnitedHealth's executive, Brian Thompson, being fatally shot in a targeted attack. This incident has shocked industry insiders as investigations continue to uncover the motive behind this alarming event.

(With inputs from agencies.)